Company intelligence / Profile preview

Celator Pharmaceuticals

Ownership: Private
Development stage: Phase 3

Overview

Celator’s lead program, Vyxeos® (CPX‑351), a liposomal formulation of cytarabine and daunorubicin, demonstrated statistically significant improvement in overall survival versus standard therapy in a Phase 3 trial for high-risk AML. Median overall survival was 9.56 months with Vyxeos vs. 5.95 months with standard care; over 40% of patients were alive after one year. The company was preparing regulatory submissions at the time of its acquisition by Jazz Pharmaceuticals in mid‑2016.

Therapeutic areas: Oncology
Modalities: Liposomal formulations (nanomedicine)Small molecules (chemotherapy agents)
Industry: Biotech

Drug pipeline

3 assets

CPX-351

Phase 3

Indications: Acute myeloid leukemia

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Celator Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celator Pharmaceuticals.

Explore the full profile